Survival Benefit Linked With Adjuvant RT+ADT in Lymph Node + PCa
Radiation treatment plus androgen deprivation therapy (ADT) after radical prostatectomy was associated with an overall survival benefit.
All articles by Jason Hoffman, PharmD, RPh
Adjuvant RT+ADT Linked With Survival Advantage in Lymph Node Positive PCa
Radiation treatment plus androgen deprivation therapy (ADT) after radical prostatectomy was associated with an overall survival benefit.
Alisertib May Help Treat Neuroendocrine Prostate Cancer
NEPC is an aggressive subtype of castration-resistant prostate cancer independent of androgen expression.
Use Metastasis-Free Survival as Proxy in Localized PCa Trials
Metastasis-free survival correlates with overall survival in localized prostate cancer clinical trials.
Radium-223 With Concomitant Therapy May Prolong Life With mCRPC
Survival was longer in patients who received radium-223 plus abiraterone, enzalutamide, or both.
No Survival Benefit With Cabozantinib in Progressive mCRPC
Cabozantinib did not increase survival of heavily treated patients with mCRPC, compared with prednisone.
PI3K Pathway Aberrations May Reveal Targeted Therapy Opportunities
Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, researchers say.
Hypofractionated RT Noninferior for Localized Prostate Cancer
For localized prostate cancer patients, hypofractionated radiation therapy at a dose of 60 Gy in fractions is effective.
Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
TRUS-biopsy Inferior for Prostate Cancer Detection
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...